NYSE · CIK 0002044725
EVMN Evommune, Inc.
Insider trading from SEC Form 4. Last filing Jul 10, 2026. Close $6.25 on Oct 9, 2026, +0% from the 52-week low and -80% from the high.
In brief
Evommune, Inc. (EVMN) has 49 SEC Form 4 filings on file from 14 insiders, the latest filed on Jul 10, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
14 open-market trades have been scored at EVMN. The newest: Kyle Carver (Chief Financial Officer) bought $13k of stock on Jul 8, 2026, filed Jul 10, 2026, scored 48 (moderate). The largest of the 14 shown: LSP 7 Cooperative UA (10% owner) bought $25M on Nov 7, 2025, scored 53 (moderate). 2 insiders bought within 14 days of each other around Jul 8, 2026.
6 Form 144 notices of planned sales are on file, the latest filed Jun 22, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Evommune, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | Kyle Carver Chief Financial Officer buy | $13k 1,000 shares | +2% | +7% from low-58% from high | |
| 60Notable | Arthur S Kirsch director buy | $133k 10,000 shares | - | +8% from low-58% from high | |
| 17Weak | Janice Suzann Drew Chief of Dev. Operations sell | $453k 20,000 shares | -23% | +50% from low-29% from high | |
| 31Weak | Luis C. Pena President & CEO sell | $169k 7,438 shares | -1% | +50% from low-29% from high | |
| 1Weak | Jeegar Pravinkumar Patel Chief Scientific Officer sell | $33k 1,488 shares | -3% | +50% from low-29% from high | |
| 30Weak | David E Cohen director sell | $123k 6,056 shares | -26% | +32% from low-37% from high | |
| 36Weak | Luis C. Pena President & CEO sell | $382k 16,787 shares | -3% | +48% from low-30% from high | |
| 21Weak | Jeegar Pravinkumar Patel Chief Scientific Officer sell | $379k 16,687 shares | -26% | +48% from low-30% from high | |
| 23Weak | Kyle Carver Chief Financial Officer sell | $415k 18,175 shares | -23% | +55% from low-26% from high | |
| 14Weak | Gregory S. Moss Chief Business & Legal Officer sell | $325k 14,223 shares | -19% | +55% from low-26% from high | |
| 21Weak | Robert Lorne Hopfner director, owner buy | $17k 1,000 shares | +33% | - | |
| 60Notable | Ra Capital Management, L.p. director, owner buy | $20M 1,250,000 shares | +82% | - | |
| 53Moderate | LSP 7 Cooperative UA owner buy | $25M 1,562,500 shares | +46% | - | |
| 61Notable | Weegen Felice Isabel Verduyn-van director, owner buy | $25M 1,562,500 shares | +46% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 22, 2026 | JANICE DREW Officer | 20,000 0.06% of outstanding | $427k | Jun 22, 2026 | none |
| Jun 2, 2026 | DAVID COHEN Director | 9,258 0.03% of outstanding | $205k | Jun 2, 2026 | none |
| Jun 1, 2026 | JEEGAR PATEL Officer | 18,175 0.05% of outstanding | $422k | Jun 1, 2026 | none |
| Jun 1, 2026 | LUIS PENA Director, Officer | 24,225 0.07% of outstanding | $563k | Jun 1, 2026 | none |
| May 28, 2026 | KYLE CARVER Officer | 25,675 0.07% of outstanding | $599k | May 28, 2026 | none |
| May 28, 2026 | GREGORY MOSS Officer | 14,223 0.04% of outstanding | $332k | May 28, 2026 | none |
Transactions
The newest 50 of 108 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | Kyle Carver Chief Financial Officer | POpen-market purchase Common Stock | +1,000 | $13.26 | $13k | 60,335 | Jul 10, 2026 |
| Jul 7, 2026 | Arthur S Kirsch director | POpen-market purchase Common Stockindirect: By Trust | +10,000 | $13.30 | $133k | 10,000 | Jul 8, 2026 |
| Jun 22, 2026 | Janice Suzann Drew Chief of Dev. Operations | MOption exercise Common Stock10b5-1 | +3,839 | $3.84 | $15k | 71,633 | Jun 24, 2026 |
| Jun 22, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +1,488 | $3.84 | $5,714 | 47,891 | Jun 24, 2026 |
| Jun 22, 2026 | Luis C. Pena President & CEO | SOpen-market sale Common Stock10b5-1 | -7,438 | $22.71 | $169k | 630,458 | Jun 24, 2026 |
| Jun 22, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -1,488 | $22.50 | $33k | 46,403 | Jun 24, 2026 |
| Jun 22, 2026 | Janice Suzann Drew Chief of Dev. Operations | MOption exercise Common Stock10b5-1 | +16,161 | $2.99 | $48k | 87,794 | Jun 24, 2026 |
| Jun 22, 2026 | Janice Suzann Drew Chief of Dev. Operations | SOpen-market sale Common Stock10b5-1 | -20,000 | $22.63 | $453k | 67,794 | Jun 24, 2026 |
| Jun 22, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -1,488 | $0.00 | $0 | 27,842 | Jun 24, 2026 |
| Jun 22, 2026 | Janice Suzann Drew Chief of Dev. Operations | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -3,839 | $0.00 | $0 | 53,795 | Jun 24, 2026 |
| Jun 22, 2026 | Janice Suzann Drew Chief of Dev. Operations | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -16,161 | $0.00 | $0 | 39,321 | Jun 24, 2026 |
| Jun 2, 2026 | Arthur S Kirsch director | AGrant or award Stock Option (Right to buy)derivative | +15,673 | $0.00 | $0 | 15,673 | Jun 3, 2026 |
| Jun 1, 2026 | Luis C. Pena President & CEO | SOpen-market sale Common Stock10b5-1 | -16,787 | $22.74 | $382k | 637,896 | Jun 3, 2026 |
| Jun 1, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +13,512 | $3.84 | $52k | 63,090 | Jun 3, 2026 |
| Jun 2, 2026 | David E Cohen director | SOpen-market sale Common Stock10b5-1 | -5,456 | $20.21 | $110k | 18,209 | Jun 3, 2026 |
| Jun 2, 2026 | Benjamin F McGraw III director | AGrant or award Stock Option (Right to buy)derivative | +15,673 | $0.00 | $0 | 15,673 | Jun 3, 2026 |
| Jun 1, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -16,687 | $22.74 | $379k | 46,403 | Jun 3, 2026 |
| Jun 2, 2026 | David E Cohen director | SOpen-market sale Common Stock10b5-1 | -600 | $21.38 | $13k | 17,609 | Jun 3, 2026 |
| Jun 1, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -13,512 | $0.00 | $0 | 29,330 | Jun 3, 2026 |
| Jun 2, 2026 | David E Cohen director | AGrant or award Stock Option (Right to buy)derivative10b5-1 | +15,673 | $0.00 | $0 | 15,673 | Jun 3, 2026 |
| May 28, 2026 | Kyle Carver Chief Financial Officer | MOption exercise Common Stock10b5-1 | +15,000 | $2.99 | $45k | 77,510 | Jun 1, 2026 |
| May 28, 2026 | Gregory S. Moss Chief Business & Legal Officer | MOption exercise Common Stock10b5-1 | +14,223 | $1.71 | $24k | 75,058 | Jun 1, 2026 |
| May 28, 2026 | Kyle Carver Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -18,175 | $22.84 | $415k | 59,335 | Jun 1, 2026 |
| May 28, 2026 | Gregory S. Moss Chief Business & Legal Officer | SOpen-market sale Common Stock10b5-1 | -14,223 | $22.83 | $325k | 60,835 | Jun 1, 2026 |
| May 28, 2026 | Kyle Carver Chief Financial Officer | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 96,731 | Jun 1, 2026 |
| May 28, 2026 | Gregory S. Moss Chief Business & Legal Officer | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -14,223 | $0.00 | $0 | 47,845 | Jun 1, 2026 |
| Apr 16, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +69,315 | $0.00 | $0 | 69,315 | Apr 17, 2026 |
| Apr 16, 2026 | Eugene Bauer Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +51,117 | $0.00 | $0 | 51,117 | Apr 17, 2026 |
| Apr 16, 2026 | Kyle Carver Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +98,946 | $0.00 | $0 | 98,946 | Apr 17, 2026 |
| Apr 16, 2026 | Janice Suzann Drew Chief of Dev. Operations | AGrant or award Employee Stock Option (Right to Buy)derivative | +73,892 | $0.00 | $0 | 73,892 | Apr 17, 2026 |
| Apr 16, 2026 | Luis C. Pena President & CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +291,420 | $0.00 | $0 | 291,420 | Apr 17, 2026 |
| Apr 16, 2026 | Gregory S. Moss Chief Business & Legal Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +115,279 | $0.00 | $0 | 115,279 | Apr 17, 2026 |
| Feb 17, 2026 | LSP 7 Cooperative UA director, owner | AGrant or award Common Stockindirect: See footnote | +358,680 | $27.88 | $10.0M | 5,288,313 | Feb 19, 2026 |
| Feb 17, 2026 | Weegen Felice Isabel Verduyn-van director, owner | AGrant or award Common Stockindirect: By LSP 7 Cooperatief U.A. | +358,680 | $27.88 | $10.0M | 5,288,313 | Feb 18, 2026 |
| Feb 17, 2026 | Ra Capital Management, L.p. director | AGrant or award Common Stockindirect: See Footnotes | +35,868 | $27.88 | $1000k | 2,710,293 | Feb 17, 2026 |
| Dec 19, 2025 | Robert Lorne Hopfner director, owner | POpen-market purchase Common Stockindirect: By Trust | +1,000 | $17.35 | $17k | 4,026 | Dec 22, 2025 |
| Dec 8, 2025 | Eugene Bauer Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Dec 19, 2025 |
| Dec 9, 2025 | Eugene Bauer Chief Medical Officer | FTax withholding Common Stock | -1,478 | $17.84 | $26k | 270,818 | Dec 11, 2025 |
| Dec 9, 2025 | Kyle Carver Chief Financial Officer | FTax withholding Common Stock | -13,290 | $17.84 | $237k | 62,510 | Dec 11, 2025 |
| Dec 9, 2025 | Janice Suzann Drew EVP, Operations | FTax withholding Common Stock | -5,074 | $17.84 | $91k | 67,794 | Dec 11, 2025 |
| Dec 9, 2025 | Luis C. Pena President & CEO | FTax withholding Common Stock | -28,138 | $17.84 | $502k | 654,683 | Dec 11, 2025 |
| Dec 9, 2025 | Gregory S. Moss Chief Business & Legal Officer | FTax withholding Common Stock | -13,624 | $17.84 | $243k | 60,835 | Dec 11, 2025 |
| Dec 9, 2025 | Jeegar Pravinkumar Patel Chief Scientific Officer | FTax withholding Common Stock | -7,513 | $17.84 | $134k | 49,578 | Dec 11, 2025 |
| Nov 7, 2025 | Eugene Bauer Chief Medical Officer | CConversion Common Stock | +25,812 | - | - | 272,296 | Nov 12, 2025 |
| Nov 7, 2025 | Kyle Carver Chief Financial Officer | CConversion Common Stock | +3,175 | - | - | 75,800 | Nov 12, 2025 |
| Nov 7, 2025 | Robert Lorne Hopfner director, owner | CConversion Common Stockindirect: By Trust | +3,026 | - | - | 3,026 | Nov 12, 2025 |
| Nov 7, 2025 | Ra Capital Management, L.p. director, owner | CConversion Common Stockindirect: See Footnotes | +1,517,329 | - | - | 1,517,329 | Nov 12, 2025 |
| Nov 7, 2025 | Pivotal bioVenture Partners Fund I, L.P. director, owner | CConversion Common Stockindirect: See footnotes | +1,441,032 | - | - | 1,441,032 | Nov 12, 2025 |
| Nov 7, 2025 | Janice Suzann Drew EVP, Operations | CConversion Common Stock | +1,587 | - | - | 72,868 | Nov 12, 2025 |
| Nov 7, 2025 | David E Cohen director | CConversion Common Stock | +6,056 | - | - | 23,665 | Nov 12, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Eugene BauerChief Medical Officer
- Kyle CarverChief Financial Officer
- David E Cohendirector
- Janice Suzann DrewChief of Dev. Operations
- Robert Lorne Hopfnerdirector, owner
- Arthur S Kirschdirector
- LSP 7 Cooperative UAowner, director
- Benjamin F McGraw IIIdirector
- Gregory S. MossChief Business & Legal Officer
- Jeegar Pravinkumar PatelChief Scientific Officer
- Luis C. PenaPresident & CEO
- Pivotal bioVenture Partners Fund I, L.P.director, owner
- Ra Capital Management, L.p.owner, director
- Weegen Felice Isabel Verduyn-vandirector, owner
Questions about EVMN
Answered from the filings on this page, as of the latest one.
Are insiders buying EVMN?
No. In the last 90 days no insider at Evommune, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade EVMN on the open market?
Kyle Carver (Chief Financial Officer) bought $13k of EVMN on Jul 8, 2026 and filed the Form 4 on Jul 10, 2026. InsiderTell scored 48 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Evommune, Inc.?
14 people have filed a Form 4 at Evommune, Inc., among them Eugene Bauer (Chief Medical Officer), Kyle Carver (Chief Financial Officer), David E Cohen (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.